Mablink Bioscience

Mablink Bioscience S.A.S., founded in 2018 and based in France, specializes in the development of Antibody Drug Conjugates (ADCs), a new class of cancer drugs. The company leverages its patented PSARlink technology, which uses hydrophilic polysarcosine to overcome the hydrophobicity of cytotoxic payloads, thereby enhancing the overall hydrophilicity and stability of ADCs. This technology allows for a higher Drug-to-Antibody Ratio (DAR) of up to 16, optimizing the therapeutic index and efficacy against tumor cells. Mablink serves pharmaceutical companies and research institutions focused on oncology, offering a platform that can be easily integrated into various stages of ADC development. The company generates revenue through partnerships and licensing agreements, providing its proprietary technology and expertise to enhance the development of targeted cancer therapies.

Keywords: ADC, cancer treatment, PSARlink, hydrophilic polysarcosine, biotechnology, oncology, drug development, therapeutic index, DAR, pharmaceutical partnerships.